CRISPR Therapeutics to Present Zugo-cel Data
The company will share clinical data on its allogeneic CAR T therapy in large B-cell lymphoma at the 68th ASH Annual Meeting.
Updated on Nov. 4, 2026 in Biotech
CRISPR Therapeutics will present clinical data from zugo-cel, an investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy targeting CD19, in patients with relapsed or refractory large B-cell lymphoma. The oral presentation, abstract 706, is scheduled for Sunday, December 13, 2026, at the 68th ASH Annual Meeting.
Why it matters
The data will come from an ongoing Phase 1/2 trial of an off-the-shelf therapy that does not require HLA matching, which could broaden access compared with patient-specific approaches. The presentation adds to the company's effort to extend CRISPR-based treatments beyond its approved sickle cell and beta thalassemia therapy.
The presentation is abstract 706 at the 68th ASH Annual Meeting, which runs December 12 to 15, 2026. The extraction does not provide efficacy or safety figures, which will be shared at the session.
The players
CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company headquartered in Zug, Switzerland, developing CRISPR-based treatments including the approved therapy CASGEVY.
American Society of Hematology (ASH)
The American Society of Hematology is a professional society of blood specialists that hosts the annual ASH Meeting and Exposition, a major venue for hematology research.
The details
Zugo-cel is administered after a standard lymphodepletion regimen and is also being studied in three autoimmune basket trials and in adult patients with relapsed or refractory B-cell malignancies. CASGEVY, approved for sickle cell disease and transfusion-dependent beta thalassemia, is described as the world's first CRISPR-based therapy.
Timeline
December 12 to 15, 2026: 68th ASH Annual Meeting takes place.
Sunday, December 13, 2026, at 5:15 p.m. CST: Zugo-cel oral presentation scheduled.
Big Picture
Zugo-cel extends the CRISPR-based therapeutic approach pioneered by CASGEVY, the first CRISPR therapy approved for sickle cell disease and transfusion-dependent beta thalassemia, into an off-the-shelf CAR T treatment for lymphoma. The move broadens CRISPR's therapeutic scope from inherited blood disorders into cancer immunotherapy.
For patients with relapsed or refractory large B-cell lymphoma, an off-the-shelf therapy that does not require HLA matching could mean treatment without a patient-specific manufacturing process, though availability depends on the trial's results. The data will be shared publicly at the December 13 presentation, so the efficacy and safety picture is not yet available.
The takeaway
Readers following gene-editing therapies should watch for the zugo-cel efficacy and safety results at the December 13 session. The outcome will indicate whether an off-the-shelf CRISPR cell therapy can work in lymphoma.
What happens next
Zugo-cel data will be presented in the oral session on Sunday, December 13, 2026, at 5:15 p.m. CST during the 68th ASH Annual Meeting, and a copy of the presentation will be posted at www.crisprtx.com once the presentation concludes.
Further reading
For more on gene-editing advances, see Biotech.
More information
A copy of the presentation will be available on the CRISPR Therapeutics company website once the session concludes.
